The potential benefit of angiotensin II-receptor antagonism is not limited to well-tolerated blood pressure control. Angiotensin II has complex effects on the heart and kidneys. Blocking the ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...